JP Morgan Initiates Neurocrine Biosciences With Overweight

Analysts at JP Morgan initiated coverage on

with a Overweight rating. The target price for Neurocrine Biosciences is set to $54. Neurocrine Biosciences shares have gained 146.60% over the past 52 weeks, while the S&P 500 index has surged 12.15% in the same period. Neurocrine Biosciences' shares declined 0.09% to close at $42.49 yesterday.